Manufacturers of over-the-counter drugs that have not been inspected before are accounting for an upward surge in drug GMP warning letters issued this year. Many of these firms appear to lack basic knowledge of GMPs and are not conducting finished product testing nor testing incoming ingredients.
Other warning letter trends are problems related to investigating batch failures, failures to prevent cross-contamination, and problems related to water testing. While data integrity is still a significant problem, it...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?